Mutuberria Ricardo, Satijn Sietske, Huijbers Angelique, Van Der Linden Edith, Lichtenbeld Hera, Chames Patrick, Arends Jan-Willem, Hoogenboom Hennie R
Department of Pathology, Maastricht University, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
J Immunol Methods. 2004 Apr;287(1-2):31-47. doi: 10.1016/j.jim.2004.01.011.
Human antibodies selectively targeting angiogenic vessels hold great promise for the immunotherapy of human malignancies and can help to elucidate the molecular mechanisms regulating angiogenesis. By selecting a large antibody phage display library on proliferating stimulated HUVEC, we have isolated 15 human antibodies that bind to HUVEC in flow cytometric analysis, 11 of which target the vasculature of colorectal carcinomas as demonstrated by immunohistochemical analysis. The four most specific antibodies, TEM-A, TEM-C, TEM-M and TEM-Q, also stain the vasculature of a series of carcinomas derived from liver, ovary, kidney, bladder, lung and breast, and either react weakly or not all with the vasculature of corresponding normal tissues. All four antibodies react with the vasculature of endometrium, but only TEM-M and TEM-Q react with the vasculature of placenta. As shown by non-reducing western blot analysis, 9/15 of the antibodies recognize either one or two distinct bands on HUVEC cell lysates, with molecular weights of 175 and/or 110-125 kDa. Antibodies identified by this approach may be used for the identification of new markers of angiogenesis and/or tumor vasculature. The selected antibodies may prove useful as new prognostic markers, for in vivo tumor imaging purposes and for further development of targeted therapies.
选择性靶向血管生成血管的人源抗体在人类恶性肿瘤免疫治疗方面具有巨大潜力,并且有助于阐明调节血管生成的分子机制。通过在增殖刺激的人脐静脉内皮细胞(HUVEC)上筛选大型抗体噬菌体展示文库,我们分离出了15种在流式细胞术分析中与HUVEC结合的人源抗体,其中11种经免疫组织化学分析证明可靶向结直肠癌的脉管系统。四种最具特异性的抗体,即TEM - A、TEM - C、TEM - M和TEM - Q,也能使源自肝脏、卵巢、肾脏、膀胱、肺和乳腺的一系列癌组织的脉管系统染色,并且与相应正常组织的脉管系统反应微弱或无反应。所有四种抗体都能与子宫内膜的脉管系统反应,但只有TEM - M和TEM - Q能与胎盘的脉管系统反应。非还原western印迹分析表明,15种抗体中有9种能识别HUVEC细胞裂解物上一条或两条不同的条带,分子量分别为175 kDa和/或110 - 125 kDa。通过这种方法鉴定的抗体可用于鉴定血管生成和/或肿瘤脉管系统的新标志物。所选抗体可能作为新的预后标志物、用于体内肿瘤成像以及靶向治疗的进一步开发具有实用价值。